FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  PJSC Pharmsynthez
2. Date of Event Requiring Statement (Month/Day/Year)
01/23/2014
3. Issuer Name and Ticker or Trading Symbol
Xenetic Biosciences, Inc. [XBIO]
(Last)
(First)
(Middle)
25 LITER KRASNOVO KURSANTA ST.
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

ST. PETERSBURG, 1Z 197 110
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 4,544,488
D
 
Series B Preferred Stock 1,454,545
D
 
Common Stock 821,567
I
By LLC SynBio, its wholly-owned subsidiary
Series A Preferred Stock 970,000
I
By LLC SynBio, its wholly-owned subsidiary

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants 07/01/2015 07/01/2020 Common Stock 606,062 $ (1) D  
Warrants 03/31/2016 03/31/2021 Common Stock 353,540 $ (1) D  
Warrants 07/01/2016 07/01/2021 Common Stock 50,506 $ (1) D  
Warrants 08/26/2016 08/26/2021 Common Stock 17,980 $ 4.95 D  
Warrants 09/09/2016 09/09/2021 Common Stock 32,526 $ 4.95 D  
Class B Warrants 11/07/2016 11/07/2021 Common Stock 1,454,545 (2) $ 4 D  
Warrants 12/31/2014 12/30/2019 Common Stock 204,394 (3) $ 25.41 I By LLC SynBio, its wholly-owned subsidiary

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
PJSC Pharmsynthez
25 LITER KRASNOVO KURSANTA ST.
ST. PETERSBURG, 1Z 197 110
    X    

Signatures

Erin J. Kirchner, Attorney-in-Fact 10/27/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Warrants are exercisable at the lesser of (i) $6.60 per share and (ii) 120% of the price per share of Xenetic Biosciences, Inc. common stock paid in its next occurring capital raise with a value of at least $7,000,000. Warrants were granted at six various dates in Q1 2016.
(2) The Reporting Person owns Class B Warrants exercisable into 1,454,545 shares of Common Stock. The exercise of such Class B Warrants is limited by the beneficial ownership limitation included in such Class B Warrants, which provides that such Class B Warrants may not be exercised if the holder thereof would own more than 4.99% of the outstanding Common Stock of the Issuer as after giving effect to such exercise. The amount of shares of Common Stock into which such Class B Warrants are exercisable was calculated for the purposes of this report without giving effect to any ownership limitation of the Reporting Person.
(3) The Reporting Person's wholly owned subsidiary, LLC SynBio, owns warrants exercisable into 204,394 shares of Common Stock. Such warrants are subject to performance vesting. The vesting milestones need to be achieved by December 31, 2017 (50%) and July 31, 2018 (50%). The amount of shares of Common Stock into which such warrants are exercisable was calculated for the purposes of this report without giving effect to any performance vesting limitations.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.